Signaling through mitogen-activated protein kinase and Rac/Rho does not duplicate the effects of activated Ras on skeletal myogenesis

Molecular and Cellular Biology

Volumn 17, Issue 7, 1997, Pages 3547-3555

  Ramocki, Melissa B ^a   Johnson, Sally E ^a   White, Michael A ^b   Ashendel, Curtis L ^c   Konieczny, Stephen F ^a   Taparowsky, Elizabeth J ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HELIX LOOP HELIX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; DNA BINDING; EFFECTOR CELL; ENZYME ACTIVITY; GENE DUPLICATION; GENETIC REGULATION; MOUSE; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REPORTER GENE; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALIA;

EID: 0030989152     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.7.3547     Document Type: Article

References (47)

1. Alema, S., and F. Tato. 1994. Oncogenes and muscle differentiation: multiple mechanisms of interference. Cancer Biol. 5:147-156.
2. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley, and A. K. Saltiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinse kinasc in vitro and in vivo. J, Biol. Chem. 270:27489-27494.
3. Bader, D., T. Masaki, and D. A. Fischman. 1982. Immunochcmical analysis of myosin heavy chain during avian myogenesis in vivo and in vitro. J. Cell Biol. 95:763-770.
4. Bos, J. L. 1989. ras oncogencs in human cancer: a review, Cancer Res. 49:4682-4689.
5. Brennan, T. J., D. G. Edmondson, L. Li, and E. N. Olson. 1991. Transforming growth factor β represses the action of myogenin through a mechanism independent of DNA binding. Proc. Natl. Acad. Sci. USA 88:3822-3826.
6. Cowley, S., H. Paterson, P, Kemp, and C. J. Marshall. 1994. Activation of MAP kinasc kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841-852.
7. Davenport, E. A., and E. J. Taparowsky. 1990. Novel phenotype of C3H 10T1/2 fibroblasts cotransfecled with the c-Ha-ras and adenovirus 5 E1A oncogenes. Mol. Carcinog. 3:83-92.
8. Denhardt, D. T. 1996. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem. J. 318:729-747.
9. Downward, J. 1995. KSR: a novel player in the RAS pathway. Cell 83:831-834.
10. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges, and A. R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92:7685-7689.
11. Gossett, L. A., W.Zhang, and E. N. Olson. 1988. Dexamethasone-dependent inhibition of differentiation of C2 myoblasts bearing steroid-inducible N-ras oncogenes. J, Cell Biol. 106:2127-2137.
12. Hallberg, B., S. I. Rayter, and J. Downward. 1994. Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J. Biol. Chem. 269:3913-3916.
13. Hardy, S., Y. Kong, and S. F. Konieczny. 1993. Fibroblast growth factor inhibits MRF4 activity independently of the phosphorylation status of a conserved threonine residue within the DNA-binding domain. Mol. Cell. Biol. 13:5943-5956.
14. Hill, C. S., J. Wynne, and R. Treisman. 1995. The Rho family GTPses RhoA, Racl, and CDC42Hs regulate transcriptional activation by SRF. Cell 81:1159-1170.
15. Johnson, S. E., X. Wang, S. Hardy, E. J. Taparowsky, and S. F. Konieczny. 1996. Casein kinase II increases the transcriptionl activities of MRF4 and MyoD independently of their direct phosphorylation. Mol. Cell. Biol. 16: 1604-1613.
16. Joneson, T., M. A. White, M. H. Wigler, and D. Bar-Sagi. 1996. Stimulation of membrane ruffling and MAP kinasc activation by distinct effectors of Ras. Science 271:810-812.
17. Khosravi-Far, R., P. A. Solski, G. J. Clark, M. S. Kinch, and C. J. Der. 1995. Activation of Racl, RhoA, and milogen-activated protein kinases is required for Ras transformation. Mol. Cell, Biol. 15:6443-6453.
18. Khosravi-Far, R., M. A. White, J. K. Westwick, P. A. Solski, M. Chrzanowska-Wodnicka, L. Van Aelst, M. H. Wigler, and C. J. Der. 1996. Oncogenic Ras activation of Raf/mitogen-activntcd protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol. Cell. Biol. 16:3923-3933.
19. val inhibits myogenesis without altering the DNA binding or transcriptional activities of the myogenic basic helix-loop-helix factors. Mol. Cell. Biol. 15:5205-5213.
20. Konieczny, S. F., B. L. Drobes, S. L. Menke, and E. J. Taparowsky. 1989. Inhibition of myogenic differentiation by the H-Ras oncogene is associated with the down regulation of the MyoD1 gene. Oncogene 4:473-481.
21. Lassar, A., and A. Munsterberg. 1994. Wiring diagrams: regulatory circuits and the control of skeletal myogenesis. Curr. Biol. 6:432-142.
22. Lassar, A. B., M. T. Thayer, R. W. Overell, and H. Weintraub. 1989. Transformation by activated ras or fos prevents myogenesis by inhibiting expression of MyoD. Cell 58:659-667.
23. Lassar, A. B., S. X. Skapek, and B. Novitch. 1994. Regulatory mechanisms that coordinate skeletal muscle differentiation und cell cycle withdrawal. Curr. Opin. Cell Biol. 6:788-794.
24. Li, L., J. Zhou, G. James, R. Heller-liarrison, M. P. Czech, and E. N. Olson. 1992. FGF inactivates myogenic helix-loop-helix proteins through phosphorylation of a conserved protein kinase C site in their DNA-binding domains. Cell 71:1181-1194.
25. Li, Y.-S., J. Y.-J. Shyy, S. Li, J. Lee, B. Su, M. Karin, and S. Chien. 1996. The Ras-JNK pathway is involved in shear-induced gene expression. Mol. Cell. Biol. 16:5947-5954.
26. Ludolph, D. C., and S. F. Konieczny. 1995. Transcription factor families: muscling in on the myogenic program. FASEB J. 9:1595-1604.
27. Marais, R., J. Wynne, and R. Treisman. 1993. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriplional activation domain. Cell 73:381-393.
28. Martin, J, F., L. Li, and E. N. Olson. 1992. Repression of myogenin function by TGF-β1 is targeted at the basic helix-loop-helix motif and is independent of E2A products. J. Biol. Chem. 267:10956-10960.
29. Moodie, S. A., B. M. Willumsen, M. J. Weber, and A. Wolfman. 1993. Complexes of Ras-GTP with Raf-1 and mitogen-aclivated protein kinase. Science 260:1658-1661.
30. Olson, E. N., G. Spizz, and M. A. Tainsky. 1987. The oncogenic forms of N-ras and H-ras prevent skeletal myoblast differentiation. Mol. Cell. Biol. 7:2104-2111.
31. Pang, L., T. Sawada, S. J. Decker, and A. R. Saltiel. 1995. Inhibition of MAP kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem. 270:13585-13588.
32. Prendergast, G. C., R. Khosravi-Far, P. A. Solski, H. Kurzawa, P. F. Lebowitz, and C. J. Der. 1995. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 10:2289-2296.
33. Qiu, R.-G., J. Chen, D. Kirn, F. McCormick, and M. Symons. 1995. An essential role for Rac in Ras transformation. Nature 374:457-159.
34. Rodriguoz-Viciana, P., P. H. Warne, R. Dhand, B. Vahnaesebrneck, I. Gout, M. J. Fry, M. D. Waterfleld, and J. Downward. 1994. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532.
35. Rudnicki, M, A., and R. Jaenisch. 1995. The MyoD family of transcription factors and skeletal myogenesis. Bioessays 17:203-219.
36. ras with phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. USA 88:7908-7912.
37. Spizz, G., D. Roman, A. Strauss, and E. N. Olson. 1986. Serum and fibroblast growth factors inhibit myogenic differentiation through a mechanism dependent on protein synthesis and independent of cell proliferation. J. Biol. Chem. 261:9483-9488.
38. Stokoe, D., S. G. Macdonald, K. Cadwallader, M, Symons, and J. F. Hancock. 1994. Activation of Raf as a result of recruitment to the plasma membrane. Science 264:1463-1467.
39. Taparowsky, E. J., M. L. Heaney, and J. T. Parsons. 1987. Oncogenemediated multistep transformation of O3H1OT1/2 cells. Cancer Res. 47: 4125-4129.
40. Urano. T., R. Emkey, and L. A. Feig. 1996. Ral-GTPnses mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. EMBO J. 15:810-816.
41. Vaidya, T. B., S. J. Rhodes, E. J. Taparowsky, and S. F. Konieczny. 1989. Fibroblast growth factor and transforming growth factor β repress transcription of the myogenic regulatory gene MyoD1. Mol. Cell. Biol. 9:3576-3579.
42. Vaidya, T. B., C. M. Weyman, D. Teegarden, C. L. Ashendel, and E. J. Taparowsky. 1991. Inhibition of myogenesis by the H-ras oncogene: implication of a role for protein kinase C. J. Cell Biol. 114:809-820.
43. Van Aelst, L., M. A. White, and M. H. Wigler. 1994. Ras partners. Cold Spring Harbor Symp. Quant. Biol. LIX:181-186.
44. Weyman, C. M., M. B. Ramocki, E. J. Taparnwsky, and A. Wolfman. 1997. Distinct signaling pathways regulate transformatiun and inhibition of skeletal muscle differentiation by oncogenic Ras. Oncogene 14:697-704.
45. White, M. A., C. Nicolette, A. Minden, A. Pnlverino, L. Van Aelst, M. Karin, and M. H. Wigler. 1995. Multiple Ras functions can contribute to mammalian cell transformation. Cell 80:533-541.
46. White, M. A., T. Vale, J. H. Camonis, E. Schaefer, and M. H. Wigler. 1996. A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation. J. Biol. Chem. 271:16439-16442.
47. Whitmarsh, A. J., P. Shore, A. D. Sharrocks, and R. J. Davis. 1995. Integration of MAP kinase signal transduction pathways at the serum response element. Science 269:403-407.